TRCT
CEROW

Tower Research Capital (TRC)’s CERo Therapeutics Warrants CEROW Stock Holding History

Tower Research Capital (TRC)’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-87
Closed -$1 – 5878
2024
Q4 		$1 Hold
87
– – ﹤0.01% 5666
2024
Q3 		$0 Hold
87
– – ﹤0.01% 6038
2024
Q2 		$2 Hold
87
– – ﹤0.01% 5640
2024
Q1 		$6 Buy
+87
New +$5 ﹤0.01% 5795

Other funds holding CEROW

CF
Cantor Fitzgerald New York $6.78B AUM 28.97% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 76.63% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $113M AUM 20.91% 1-Year Est. Return

Tower Research Capital (TRC)'s CEROW Position: Q1 2025 in Review

Tower Research Capital (TRC) sold out of CERo Therapeutics Warrants (CEROW) in Q1 2025, closing a stake of 87 shares — an estimated $1 sold.

Tower Research Capital (TRC) first reported a position in CEROW in Q1 2024 and held it in 4 quarters. The position peaked at $6 in Q1 2024. 26 funds tracked by Wall St. Rank hold CEROW as of Q1 2025.

  • Tower Research Capital (TRC) reported no remaining CERo Therapeutics Warrants position as of Q1 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 87 CERo Therapeutics Warrants shares in Q1 2025, an estimated $1.
  • Tower Research Capital (TRC) first reported a position in CERo Therapeutics Warrants in Q1 2024 and held it in 4 quarters.
  • Tower Research Capital (TRC)'s CERo Therapeutics Warrants position peaked at $6 in Q1 2024.
  • 26 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q1 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2025, filed 15 May 2025.